{"id":3755,"date":"2025-03-31T18:11:49","date_gmt":"2025-03-31T18:11:49","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/bumetanide-txt\/"},"modified":"2025-03-31T18:11:49","modified_gmt":"2025-03-31T18:11:49","slug":"bumetanide-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/bumetanide-txt\/","title":{"rendered":"Bumetanide.txt"},"content":{"rendered":"

Bumetanide<\/h1>\n

CLINICAL USE <\/H3>
\nLoop diuretic

DOSE IN NORMAL RENAL FUNCTION <\/H3><\/p>\n
  • Oral: 1\u201310 mg daily, may be given in 2 divided doses\n
  • Injection: IV 1\u20132 mg repeated after 20 minutes; IM if necessary, 1 mg then adjust according to response\n
  • IV infusion : 2\u20135 mg over 30\u201360 minutes

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :364.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :95<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.2\u20130.5<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :0.75\u20132.6\/1.5

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect with NSAIDs\n
  • Anti-arrhythmics: risk of cardiac toxicity with anti-arrhythmics if hypokalaemia occurs; effects of lidocaine and mexiletine antagonised\n
  • Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid concomitant use with lymecycline\n
  • Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics\n
  • Anti-epileptics: increased risk of hyponatraemia with carbamazepine\n
  • Antifungals: increased risk of hypokalaemia with amphotericin\n
  • Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalaemia occurs\n
  • Antipsychotics: increased risk of ventricular arrhythmias with amisulpride, sertindole or pimozide if hypokalaemia occurs \u2013 avoid with pimozide; enhanced hypotensive effect with phenothiazines\n
  • Atomoxetine: increased risk of ventricular arrhythmias if hypokalaemia occurs\n
  • Cardiac glycosides: increased toxicity if hypokalaemia occurs\n
  • Lithium: risk of toxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV, IM

    Rate of Administration <\/H4>

    IV infusion <\/H4>: 2\u20135 mg in 500 mL of infusion fluid over 30\u201360 minutesIV bolus: 1\u20132 mg over 3\u20134 minutes

    Comments<\/H4>Compatible with glucose 5% or sodium chloride 0.9%

    OTHER INFORMATION <\/H4>\n
  • 1 mg bumetanide \u2261 40 mg furosemide at low doses, but avoid direct substitution at high doses\n
  • In patients with severe chronic renal failure given high doses of bumetanide there are reports of musculoskeletal pain and muscle spasm\n
  • Orally: diuresis begins within 30 minutes, peaks after 1\u20132 hours, lasts 3 hours\n
  • IV: diuresis begins within few minutes and ceases in about 2 hours\n
  • Use with caution in patients receiving nephrotoxic or ototoxic drugs\n
  • Smaller doses may be sufficient in the elderly and cirrhotics (500 micrograms)\n
  • Use twice daily for higher doses .
    \n","protected":false},"excerpt":{"rendered":"

    Bumetanide CLINICAL USE Loop diuretic DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3755","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3755"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3755\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}